index: hide

| Genetic Alteration (ie, Driver event) | Available Targeted Agents with Activity Against Driver Event in Lung Cancer |
|---------------------------------------|-----------------------------------------------------------------------------|
| High-level MET amplification or MET exon 14 skipping mutation | Crizotinib {gen.nscl.principles.h.'1},{gen.nscl.principles.h.'2},{gen.nscl.principles.h.'3},{gen.nscl.principles.h.'4},{gen.nscl.principles.h.'5} |
| RET rearrangements | Cabozantinib {gen.nscl.principles.h.'6},{gen.nscl.principles.h.'7} <br />Vandetanib {gen.nscl.principles.h.'8} |
| ERBB2 (HER2) mutations | Ado-trastuzumab emtansine {gen.nscl.principles.h.'9} |
| Tumor mutational burden (TMB)* | Nivolumab + ipilimumab {gen.nscl.principles.h.'10} <br />Nivolumab {gen.nscl.principles.h.'11} |

\* TMB is an evolving biomarker that may be helpful in selecting patients for immunotherapy. There is no consensus on how to measure TMB.
